FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer

被引：2
|
作者：
Cervantes, A. [1 ]
Prager, G. W. [2 ]
机构：
[1] Univ Valencia, Hosp Clin Univ, Biomed Res Inst, Dept Med Oncol,INCLIVA, Valencia, Spain
[2] Med Univ Vienna, Dept Med 1, Vienna, Austria
来源：
ESMO OPEN | 2023年 / 8卷 / 02期
关键词：
METASTATIC COLORECTAL-CANCER; OPEN-LABEL; PHASE-II; FOLFIRI; FLUOROURACIL; OXALIPLATIN; MULTICENTER; LEUCOVORIN; CETUXIMAB; SURVIVAL;
D O I：
10.1016/j.esmoop.2023.100883
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials
    You, Xia-Hong
    Jiang, Yu-Huan
    Fang, Zhou
    Sun, Fan
    Li, Yao
    Wang, Wei
    Xia, Zi-Jin
    Wang, Xiao-Zhong
    Ying, Hou-Qun
    [J]. ESMO OPEN, 2020, 5 (02)
  • [32] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    [J]. MEDICINE, 2016, 95 (51) : e4531
  • [33] A multicenter randomized phase II trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study
    Bando, Hideaki
    Satake, Hironaga
    Kotani, Daisuke
    Hamaguchi, Tetsuya
    Shiozawa, Manabu
    Ikumoto, Taro
    Okita, Yoshihiro
    Masuishi, Toshiki
    Kagawa, Yoshinori
    Yasui, Hisateru
    Oki, Eiji
    Komatsu, Yoshito
    Taniguchi, Hiroya
    Muro, Kei
    Kotaka, Masahito
    Yamazaki, Kentaro
    Misumi, Toshihiro
    Yoshino, Takayuki
    Kato, Takeshi
    Tsuji, Akihito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer
    Oukkal, M.
    Kara, F.
    Difi, S.
    Bouzidi, D.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Bevacizumab as first-line therapy for advanced breast cancer
    Bartsch, R.
    de Vries, C.
    Foedermayr, M.
    Mader, R. M.
    Huber, M.
    Bago-Horvath, Z.
    Pluschnig, U.
    Steger, G. G.
    Dubsky, P.
    Fitzal, F.
    Schreil, G.
    Zielinski, C. C.
    Gampenrieder, S. P.
    Ziebermayr, R.
    [J]. ONKOLOGIE, 2010, 33 : 16 - 16
  • [36] Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Fioravanti, A.
    Orlandi, P.
    Salvatore, L.
    Masi, G.
    Di Desidero, T.
    Canu, B.
    Schirripa, M.
    Frumento, P.
    Di Paolo, A.
    Danesi, R.
    Falcone, A.
    Bocci, G.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1262 - 1269
  • [37] Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    F Loupakis
    C Cremolini
    A Fioravanti
    P Orlandi
    L Salvatore
    G Masi
    T Di Desidero
    B Canu
    M Schirripa
    P Frumento
    A Di Paolo
    R Danesi
    A Falcone
    G Bocci
    [J]. British Journal of Cancer, 2011, 104 : 1262 - 1269
  • [38] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [39] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Clinical Outcomes of Bevacizumab (BV) plus XELOX Combination for the First-line Treatment of Patients (pts) With Advanced Cancer of the Colon or Rectum (ACRC) - Preliminary Results of the OBELIX Study
    Pastorelli, D.
    Latiano, T.
    Antonuzzo, L.
    Pavese, I.
    Aieta, M.
    Algeri, R.
    Azzarello, D.
    Bertolini, A.
    Di Fabio, F.
    Di Costanzo, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S426 - S426
12345